Articles related to INSURANCE

In an era where specialty drug costs soar, Alternative Funding Programs present a complex solution, balancing cost containment with patient access to essential medications. These programs, while offering potential savings, may also introduce treatment delays and increased financial burdens for patients.

The ACA’s preventive care mandate, currently under constitutional review, has significantly impacted rates of cancer screenings and early-stage diagnoses. The outcome of this case could reshape the landscape of preventive care in oncology.

The proposed changes to the 2024 MPFS could have far-reaching implications for oncology care; stay informed to understand how these changes may impact your practice and patient outcomes.

Discover how a recent class-action lawsuit against Bristol Myers Squibb could impact the availability and cost of multiple myeloma treatment options.

Discover how the 340B Drug Pricing Program influences prescription trends toward higher-cost biologics over biosimilars, and what this means for cost-effective healthcare.

New research underscores the dramatic increase in prior authorization for oral oncology drugs under Medicare Part D. Understand the implications for your practice as insurers tighten their grip on treatment decisions.